Lara Sullivan - 31 Mar 2025 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
President ,CEO & CMO, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Issuer symbol
PYXS
Transactions as of
31 Mar 2025
Net transactions value
+$899,942
Form type
4
Filing time
02 Apr 2025, 09:06:50 UTC
Previous filing
23 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $899,942 +918,308 $0.9800 918,308 31 Mar 2025 Common Stock 918,308 $0.9800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date.